Chapters
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 | Atropine injection | ||
| Domperidone suppositories | Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. | |
| Domperidone suspension | Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. | |
| Domperidone tablets | Second line - domperidone should not be used by people who have serious underlying heart conditions. It should only be used in the relief of symptoms of nausea and vomiting and at the lowest effective dose for the shortest possible duration. Adults should take no more than three 10mg tablets per day. Domperidone should no longer be used to treat other conditions such as heartburn, bloating or relief of stomach discomfort. | |
| Hyoscine butylbromide injection | ||
| Hyoscine butylbromide tablets | ||
| Mebeverine tablets 135mg | ||
| Metoclopramide injections | Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects | |
| Metoclopramide suspension | Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects | |
| Metoclopramide tablets | Not recommended for patients aged 20 years and below due to risk of dystonic reactions. MHRA guidance - metroclopramide: risk of neurological adverse effects | |
| Peppermint oil capsules (Mintec) | ||
 | Peppermint water | Unlicensed | |
 | Propantheline | Specialist recommendation for hyperhidrosis |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
